The association between platelet-related parameters and nonalcoholic fatty liver disease in a metabolically healthy nonobese population

Choe, Eun Kyung; Kang, Hae Yeon

doi:10.1038/s41598-024-56796-7

Cited by 3 publications

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, our observations revealed that PLR exhibited higher diagnostic accuracy for NAFLD among the non-diabetic population compared to the diabetic population (AUCROC=0.804/AUCROC=0.762). Additionally, PLR was found to be associated with NAFLD specifically within the non-obese population ( 25 ), aligning with the observation ( 26 ) that the risk of detecting NAFLD in patients with obstructive sleep apnea–hypopnea syndrome via PLR was more favorable in those with a BMI <28 kg/m². This suggests that the non-metabolic disorders population may be more appropriate for the application of PLR.…”

Section: Discussionsupporting

confidence: 75%

The predictive role of the platelet-to-lymphocyte ratio for the risk of non-alcoholic fatty liver disease and cirrhosis: a nationwide cross-sectional study

Yan,

Zhang,

Xiao

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundThe associations between platelet-to-lymphocyte ratio (PLR) and non-alcoholic fatty liver disease (NAFLD) and cirrhosis are unclear, and there are still no effective means for diagnosing or monitoring disease progression.MethodsData from the National Health and Nutrition Examination Surveys were collected for analysis. Logistic regression and restricted cubic splines were used to evaluate the associations between PLR and NAFLD and cirrhosis in different populations. The Area Under Curve Receiver Operating Characteristic (AUCROC) was used to distinguish the models. Threshold analysis was performed by constructing a two-piecewise linear regression. Correlation analysis was performed separately on either side of the inflection point.ResultsA total of 5724 adults were included. Logistic regression analysis revealed that the PLR was associated with NAFLD and cirrhosis (AUCROC of NAFLD: 0.803; AUCROC of cirrhosis: 0.851). The AUCROC of the PLR for predicting NAFLD incidence was 0.762 in the diabetic population and 0.804 in the nondiabetic population. High PLR predicted cirrhosis in the diabetic population, with an AUCROC of 0.824, whereas a high PLR was not associated with cirrhosis in the nondiabetic population. The restricted cubic spline revealed a negative linear correlation between the PLR and NAFLD incidence. The inflection point of the PLR for NAFLD was 180.74. A PLR ≤180.74 was statistically significant (odds ratio=0.997, 95% confidence interval=0.995-0.999). In the NAFLD population, the PLR was negatively correlated with cirrhosis at a PLR ≤130.5 (odds ratio=0.987, 95% confidence interval=0.977-0.996) and positively correlated with cirrhosis at a PLR > 130.5 (odds ratio=1.006, 95% confidence interval=1.001-1.012).ConclusionsThe PLR and NAFLD were negatively correlated in the U.S. population. The PLR had a U-shaped relationship with cirrhosis in the NAFLD population. The PLR has potential value in monitoring NAFLD patient progression to cirrhosis.

show abstract

Section: Discussionsupporting

confidence: 75%

The predictive role of the platelet-to-lymphocyte ratio for the risk of non-alcoholic fatty liver disease and cirrhosis: a nationwide cross-sectional study

Yan,

Zhang,

Xiao

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

Fetuin-A: a relevant novel serum biomarker for non-invasive diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD): a retrospective case-control study

Elhoseeny,

Abdulaziz,

Mohamed

et al. 2024

BMC Gastroenterol

View full text Add to dashboard Cite

Objectives To determine how fetuin-A contributes to diagnosing and assessing MASLD severity. Methods Fifty MASLD patients and fifty healthy control participants were involved in this retrospective case-control research. Abdominal ultrasonography, fibroscan with controlled attenuated parameter scan (CAP scan), laboratory investigation (including fetuin-A assessment), clinical examination, and history-taking were performed on every case. Results Fetuin-A level was considerably higher in the Cases group (1154.85 ± 629.89) than in the Control group (505.29 ± 150.4) (p < 0.001). Fetuin-A had significant validity in the prediction of MASLD at a cut-off > 702.5 with 82% sensitivity, 90% specificity, and 86% overall accuracy. Conclusion One possible marker for MASLD diagnosis could be fetuin-A. Furthermore, a substantial association between such marker and the severity of the disease as it revealed a significant correlation with ultrasound grading and fibroscan with controlled attenuated parameters. Trial registration 1- Pan African Clinical Trial Registry. Unique Identifying number/registration ID: PACTR202309644280965. URL: https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=26860. Registration Approval date: 21/09/2023. 2- ClinicalTrials.gov. Unique Identifying number /registration ID: NCT06097039. URL: https://clinicaltrials.gov/study/NCT06097039?cond=NCT06097039&rank=1. Registration Approval date: 25/10/2023.

show abstract

Associations between Systemic Inflammatory Biomarkers and Metabolic Dysfunction Associated Steatotic Liver Disease: Findings from NHANES

Qiu,

Shen,

et al. 2024

Preprint

View full text Add to dashboard Cite

Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) represents the most prevalent form of chronic liver disease and can progress to cirrhosis and hepatocellular carcinoma (HCC). While systemic inflammatory biomarkers have been linked to various liver diseases, their roles in MASLD remain uncertain. This cross-sectional study enrolled 6613 adults aged 20 years or older from the National Health and Nutrition Examination Survey (NHANES) spanning from 2017 to March 2020. The study incorporated 10 inflammatory biomarkers, including ALI, SIRI, SII, SIPS, IBI, NLR, PLR, CAR, LMR, and PNI. Logistic regression, RCS regression, segmented regression, and subgroup analyses were implemented to explore the relationship between systemic inflammatory biomarkers and MASLD. After adjusting for vital confounders, half of the examined markers exhibited a significant association with MASLD, especially ALI, IBI, PLR, and CAR (P < 0.001). Most of these systemic inflammatory biomarkers, including ALI, SIRI, IBI, CAR, LMR, and PNI, demonstrated an obvious non-linear correlation with MASLD (P < 0.05). Moreover, the majority of these markers (SIRI, SII, IBI, NLR, PLR, and PNI) displayed notable variations in their associations with MASLD among various BMI categories (P < 0.05). In conclusion, systemic inflammatory biomarkers demonstrated a significant association with MASLD risk. Further large-scale prospective studies may be warranted to validate this relationship.

show abstract

The association between platelet-related parameters and nonalcoholic fatty liver disease in a metabolically healthy nonobese population

Cited by 3 publications

References 43 publications

The predictive role of the platelet-to-lymphocyte ratio for the risk of non-alcoholic fatty liver disease and cirrhosis: a nationwide cross-sectional study

The predictive role of the platelet-to-lymphocyte ratio for the risk of non-alcoholic fatty liver disease and cirrhosis: a nationwide cross-sectional study

Fetuin-A: a relevant novel serum biomarker for non-invasive diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD): a retrospective case-control study

Associations between Systemic Inflammatory Biomarkers and Metabolic Dysfunction Associated Steatotic Liver Disease: Findings from NHANES

Contact Info

Product

Resources

About